Cargando…
Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis
The purpose of this study was to determine what patient and pulmonary vein characteristics at the diagnosis of intraluminal pulmonary vein stenosis (PVS) are predictive of individual vein outcomes. A retrospective, single-center, cohort sub-analysis of individual pulmonary veins of patients enrolled...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000090/ https://www.ncbi.nlm.nih.gov/pubmed/33802089 http://dx.doi.org/10.3390/children8030210 |
_version_ | 1783670925804175360 |
---|---|
author | Callahan, Ryan Gauvreau, Kimberlee Marshall, Audrey C. Sena, Laureen M. Baird, Christopher W. Ireland, Christina M. McEnaney, Kerry Bjornlund, Elsa C. Mendonca, Juliana T. Jenkins, Kathy J. |
author_facet | Callahan, Ryan Gauvreau, Kimberlee Marshall, Audrey C. Sena, Laureen M. Baird, Christopher W. Ireland, Christina M. McEnaney, Kerry Bjornlund, Elsa C. Mendonca, Juliana T. Jenkins, Kathy J. |
author_sort | Callahan, Ryan |
collection | PubMed |
description | The purpose of this study was to determine what patient and pulmonary vein characteristics at the diagnosis of intraluminal pulmonary vein stenosis (PVS) are predictive of individual vein outcomes. A retrospective, single-center, cohort sub-analysis of individual pulmonary veins of patients enrolled in the clinical trial NCT00891527 using imatinib mesylate +/− bevacizumab as adjunct therapy for the treatment of multi-vessel pediatric PVS between March 2009 and December 2014 was performed. The 72-week outcomes of the individual veins are reported. Among the 48 enrolled patients, 46 patients and 182 pulmonary veins were included in the study. Multivariable analysis demonstrated that patients with veins without distal disease at baseline (odds ratio, OR 3.69, 95% confidence interval, CI [1.52, 8.94], p = 0.004), location other than left upper vein (OR 2.58, 95% CI [1.07, 6.19], p = 0.034), or veins in patients ≥ 1 y/o (OR 5.59, 95% CI [1.81, 17.3], p = 0.003) were at higher odds of having minimal disease at the end of the study. Veins in patients who received a higher percentage of eligible drug doses required fewer reinterventions (IRR 0.76, 95% CI [0.68, 0.85], p < 0.001). The success of a multi-modal treatment approach to aggressive PVS depends on the vein location, disease severity, and drug dose intensity. |
format | Online Article Text |
id | pubmed-8000090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80000902021-03-28 Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis Callahan, Ryan Gauvreau, Kimberlee Marshall, Audrey C. Sena, Laureen M. Baird, Christopher W. Ireland, Christina M. McEnaney, Kerry Bjornlund, Elsa C. Mendonca, Juliana T. Jenkins, Kathy J. Children (Basel) Article The purpose of this study was to determine what patient and pulmonary vein characteristics at the diagnosis of intraluminal pulmonary vein stenosis (PVS) are predictive of individual vein outcomes. A retrospective, single-center, cohort sub-analysis of individual pulmonary veins of patients enrolled in the clinical trial NCT00891527 using imatinib mesylate +/− bevacizumab as adjunct therapy for the treatment of multi-vessel pediatric PVS between March 2009 and December 2014 was performed. The 72-week outcomes of the individual veins are reported. Among the 48 enrolled patients, 46 patients and 182 pulmonary veins were included in the study. Multivariable analysis demonstrated that patients with veins without distal disease at baseline (odds ratio, OR 3.69, 95% confidence interval, CI [1.52, 8.94], p = 0.004), location other than left upper vein (OR 2.58, 95% CI [1.07, 6.19], p = 0.034), or veins in patients ≥ 1 y/o (OR 5.59, 95% CI [1.81, 17.3], p = 0.003) were at higher odds of having minimal disease at the end of the study. Veins in patients who received a higher percentage of eligible drug doses required fewer reinterventions (IRR 0.76, 95% CI [0.68, 0.85], p < 0.001). The success of a multi-modal treatment approach to aggressive PVS depends on the vein location, disease severity, and drug dose intensity. MDPI 2021-03-10 /pmc/articles/PMC8000090/ /pubmed/33802089 http://dx.doi.org/10.3390/children8030210 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Callahan, Ryan Gauvreau, Kimberlee Marshall, Audrey C. Sena, Laureen M. Baird, Christopher W. Ireland, Christina M. McEnaney, Kerry Bjornlund, Elsa C. Mendonca, Juliana T. Jenkins, Kathy J. Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title | Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title_full | Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title_fullStr | Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title_full_unstemmed | Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title_short | Outcomes in Establishing Individual Vessel Patency for Pediatric Pulmonary Vein Stenosis |
title_sort | outcomes in establishing individual vessel patency for pediatric pulmonary vein stenosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000090/ https://www.ncbi.nlm.nih.gov/pubmed/33802089 http://dx.doi.org/10.3390/children8030210 |
work_keys_str_mv | AT callahanryan outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT gauvreaukimberlee outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT marshallaudreyc outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT senalaureenm outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT bairdchristopherw outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT irelandchristinam outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT mcenaneykerry outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT bjornlundelsac outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT mendoncajulianat outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis AT jenkinskathyj outcomesinestablishingindividualvesselpatencyforpediatricpulmonaryveinstenosis |